chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Vaccine thawed for only 45 minutes; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 08-Mar-2021 and was forwarded to Moderna on 09-Mar-2021.    This spontaneous case was reported by a health care professional (subsequently medically confirmed) and describes the occurrence of WRONG TECHNIQUE IN DEVICE USAGE PROCESS (Vaccine thawed for only 45 minutes) in a 64-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027A21A) for an unknown indication.     No Medical History information was reported.    On 08-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 08-Mar-2021, the patient experienced WRONG TECHNIQUE IN DEVICE USAGE PROCESS (Vaccine thawed for only 45 minutes). On 08-Mar-2021, WRONG TECHNIQUE IN DEVICE USAGE PROCESS (Vaccine thawed for only 45 minutes) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route), the reporter did not provide any causality assessments.   No relevant concomitant medications reported.  No treatment information was provided.
Swelling of the face, Pt. was to ER at 1:45 PM By.
After patient received his vaccine, he had chills; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP).  A male patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose number unknown, single for covid-19 immunisation. Relevant medical history included: "Covid 19", start date: Nov2020 (unspecified if ongoing), notes: mild; "Lost sense of taste and smell " (unspecified if ongoing); "Lost sense of taste and smell " (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: CHILLS (non-serious), outcome "unknown", described as "After patient received his vaccine, he had chills". No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
I started to feel weird. I was also feeling out of it. I was also feeling tingling from my finger tips up both arms.
Patient states she had pain and swelling in left arm, headache, nausea and vomiting began Wed. morning (9/24/14) and visited P.A. and was prescribed an antibiotic and anti-inflammatory.
the patient did not have any other adverse events.; The caller said VARIVAX was administered after a temperature excursion.; This spontaneous report was received from a medical assistant referring to a patient of unknown age and gender. The patient's pertinent medical history, concomitant medications, concurrent conditions, and previous drug reactions or allergies were not reported.  On an unknown date, varicella virus vaccine live (oka/merck) (VARIVAX) underwent a temperature excursion at temperature -10.4C with time frame 30 hours. There was no previous temperature excursion.  On 16-SEP-2022, the patient was vaccinated with varicella virus vaccine live (oka/merck) (VARIVAX) subcutaneous injection, 1 dose, lot #w011626, expiration date: 06-APR-2024, administered for prophylaxis (strength, and route of administration were not provided) (Product storage error). The patient did not have any other adverse events (No adverse event).  This is one of two reports received from the same reporter.; Sender's Comments:  US-009507513-2209USA007224:
expired vaccine is stored on refrigerator on 14-Oct-2021 and then administered on 05-NOV-2021; 606 doses were given after expiration date; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (606 doses were given after expiration date) and PRODUCT STORAGE ERROR (expired vaccine is stored on refrigerator on 14-Oct-2021 and then administered on 05-NOV-2021) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 008C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 05-Nov-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 05-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (606 doses were given after expiration date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (expired vaccine is stored on refrigerator on 14-Oct-2021 and then administered on 05-NOV-2021). At the time of the report, EXPIRED PRODUCT ADMINISTERED (606 doses were given after expiration date) and PRODUCT STORAGE ERROR (expired vaccine is stored on refrigerator on 14-Oct-2021 and then administered on 05-NOV-2021) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported. No treatment medications were reported.  The vial was placed in the refrigerator on 14-Oct-2021.Vial did not undergo any temperature excursion. No adverse event was reported.
pt recv vax & 15NOV96 pt exp heaviness in the chest, dec appetite, h/a, dizziness, diarrhea, weakness, arthralgia, myalgia, foggy feeling in the head, noc sweats & chills;lost 14 pounds by 5JAN97;t100,anemic;internal bleeding confirmed;
Pain and throbbing in (right) arm that flu shot was given in. Hurting ever since got the shot (11/29/16). Advised to speak with her dr.
Raised rash covering entire left thigh and fluid filled blisters 2-3 days after vaccine.
Nausea, Continued Vomiting, Dizzy - Unable to stand, Extreme exhaustion
terrible diarrhea; Patient started with nausea 4 days after receiving 2nd dose; vomiting; This spontaneous case was reported by a consumer and describes the occurrence of DIARRHOEA (terrible diarrhea), NAUSEA (Patient started with nausea 4 days after receiving 2nd dose) and VOMITING (vomiting) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 046B21A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included GABAPENTIN, LOSARTAN and PAROXETINE HYDROCHLORIDE (PAXIL [PAROXETINE HYDROCHLORIDE]) for an unknown indication.    On 15-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 2 dosage form. On 18-Apr-2021, the patient experienced DIARRHOEA (terrible diarrhea), NAUSEA (Patient started with nausea 4 days after receiving 2nd dose) and VOMITING (vomiting). At the time of the report, DIARRHOEA (terrible diarrhea), NAUSEA (Patient started with nausea 4 days after receiving 2nd dose) and VOMITING (vomiting) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       no treatment was reported
Shortness of breath (felt as though I was holding my breath); Irregular heart heart; Lethargic, dizzy, totally exhausted after the minimum of effort, AFib; Ventricular arrhythmia; continuous running nasal drip;  I had 3 of the 5 symptoms for AFib for perhaps 14-15 months. Just wrote it off as aging process. I have had incredible good health all of my life. I am absolutely convinced that the only thing that I differently between 2020 & 2021 was to receive 1 Covid injection.  Almost immediately my neck between my right ear and rt should had and still has a 'knot' that is very painful. I am unable to completely turn my head to the right. I went to an Orthopedic doctor, received 2 cortizone injections in rt shoulder which had no positive effect. Pin persists today.
Information has been received from a lawyer regarding a case in litigation concerning a female patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient's healthcare providers recommended and/or prescribed ZOSTAVAX to the patient for its intended purpose of permanent prevention and protection against shingles and zoster-related conditions. In 2015, a healthcare provider administered the ZOSTAVAX to the patient (lot number, dosage and route of administration not provided). On or about 13-DEC-2016, the patient was treated by a healthcare provider for shingles and post herpetic neuralgia. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX, and suffered serious physical, emotional, and economic damages as a result of the patient's injuries. As a direct and proximate result of the ZOSTAVAX vaccine, the patient has and will continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs including care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; lost wages; loss of earnings capacity; and other losses and damages. The outcome of the events was considered to be not recovered. Additional information has been requested.
She is due for PREVNAR 13 and we gave that today and then she had some itching following that on her arms. There is no swelling of her mouth or throat her lips and gave her some IM BENADRYL with resolution of her symptoms. She can take some oral BENADRYL at home as needed.
Jansen COVID-19 Chills, fever, dizziness, lasting till 6am and again at 9:30. General muscle soreness.
Narrative: 63yo male pt felt dizzy and slow to answer questions ~15 minutes after receiving covid-19 (J&J) vaccine. Vaccine clinic transfered pt to Emergency Dept. where it was determined pt was having a stroke. Pt with prior hx of CVA. Pt states "I felt like I was going to pass out." Pt BG 107 at triage. BP: 127/84 P: 75 R: 18 WT: T: 98.5 HT: Pt was given TPA 9mg iv bolus and 81mg infusion. Pt was then transferred to stroke center hospital for higher level care.
A ringing on both ears/ tinnitus; second dose seemed like a larger dose than the first; Lost taste/ barely taste/ He can barely taste coffee, can't taste vinegar/ does not have taste; This spontaneous case was reported by a consumer and describes the occurrence of AGEUSIA (Lost taste/ barely taste/ He can barely taste coffee, can't taste vinegar/ does not have taste), TINNITUS (A ringing on both ears/ tinnitus) and ACCIDENTAL OVERDOSE (second dose seemed like a larger dose than the first) in a 56-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 051C21A and 051C21A) for COVID-19 vaccination.     No Medical History information was reported.   On 20-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 17-Aug-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 21-Aug-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced AGEUSIA (Lost taste/ barely taste/ He can barely taste coffee, can't taste vinegar/ does not have taste). On an unknown date, the patient experienced TINNITUS (A ringing on both ears/ tinnitus) and ACCIDENTAL OVERDOSE (second dose seemed like a larger dose than the first). At the time of the report, AGEUSIA (Lost taste/ barely taste/ He can barely taste coffee, can't taste vinegar/ does not have taste) and TINNITUS (A ringing on both ears/ tinnitus) outcome was unknown and ACCIDENTAL OVERDOSE (second dose seemed like a larger dose than the first) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No Concomitant medication was reported.  No treatment medications were reported  Patient wants some medical advice over the situation   This case was linked to MOD-2021-305910 (Patient Link).
Tertiary spread of vaccinia due to inadvertent inoculation. Her brother was secondary case exposed to military Smallpox vaccine during wrestling match 2/27/10 she was household contact of brother (onset 3/1/10). 05/13/2010 Follow up: Developed vaccina from same individual as 384016, 384017 and 384018.
Fever, headache, loss of appetite. 3 days for headache, 2 days for fever, 1 day for loss of appetite. Treated with 400 mg Ibuprofen. Resolved on its own.
This case was reported by a consumer and described the occurrence of red face in a elderly female patient who received SHINGRIX. On 11th April 2018, the patient received the 1st dose of SHINGRIX. On 12th April 2018, 1 days after receiving SHINGRIX, the patient experienced red face and feeling of warmth facial. On 13th April 2018, the outcome of the red face and feeling of warmth facial were recovered/resolved. It was unknown if the reporter considered the red face and feeling of warmth facial to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. The patient received 1st dose of SHINGRIX vaccine administered by the pharmacist. On 12th April 2018 morning, the patient awoke with beet red face, hot face and no temperature. It was persisted whole day. On 13th April 2018 morning, the patient's face was back to normal and she informed her physician, who had prescribed the vaccine and was advised not to have the 2nd dose. The patient also informed the Center of Disease Control.
Loss of appetite, Chills, fever, chest pain. Took a gram of Tylenol per day.
Information has been received concerning a 68 year old female patient who on an unspecified date was vaccinated with a dose of PNEUMOVAX 23 (Lot # not reported). Subsequently, the patient experienced a high temperature, swelling, pain, and redness at the injection site after she received PNEUMOVAX 23. The patient's high temperature required her to take antibiotics (manufacturer unspecified). It was unknown if the patient sought medical attention. At the time of the report, the outcome of the event was unknown. All telephone attempts to obtain follow-up information have been unsuccessful. The health care professional contacted during telephone follow-up could not supply the following information: patient name, date of birth, dates of vaccination, lot number, date of event, or recovery status. Follow-up information has been received from an office manager concerning a retired patient who was vaccinated, subcutaneously with the first dose of PNEUMOVAX 23 (Lot # 663888/0627Y). It was reported that the patient also experienced infection at the injection site after vaccination. The patient sought medical attention via doctor visit. This is one of several reports received from the same source. Additional information has been requested.
headache; Rapid heart beat; Arm soreness; chills; sick; Diarrhea; This case was reported by a consumer and described the occurrence of sickness in a male patient who received Herpes zoster (Shingrix) for prophylaxis.   On 5th December 2020, the patient received the 1st dose of Shingrix. In December 2020, less than a week after receiving Shingrix, the patient experienced sickness, diarrhea, headache, chills, heartbeats increased and pain in arm. On an unknown date, the outcome of the sickness, diarrhea, chills, heartbeats increased and pain in arm were recovered/resolved and the outcome of the headache was unknown.   It was unknown if the reporter considered the sickness, diarrhea, headache, chills, heartbeats increased and pain in arm to be related to Shingrix.  Addditional details were reported as follows: The age at vaccination was not reported. The patient received the dose of Shingrix and experienced some arm soreness for 4 days, rapid heart beat for 1.5 days, chills, diarrhea and felt sick for 4 days. The reporter consented to follow up. Date of birth was not provided. This case has been linked with case ID US2020246524, reported by same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020246524:same reporter
pt recv vax 2OCT96 & 9OCT96 pt exp extreme dryness in mouth & worsening of the dryness of eyes;woke up two to three times a noc & had to use water to moisten dry mouth;visit to rheumatologist was required;
Pt ran a low grade fever for 24 hours after vaccinations, and over the next month he delined in regards to cognition.  He quit talking, lost eye contact, did not respond to his name, declined in his gross & fine motor abilities.  03/11/2008 MR received from PCP showing WCCs beginning 6/18/2004. Healthy with normal development noted at 9/9 and 12/9 2005 visits.  Speech regression noted at 6/7/06 visit and DX of Autism at 6/15/07 visit.  In therapy for speech delay. 3/31/08 MR received from ped dev specialist with dx c/w Autism. Pt had language regression and shows speech delays and poor communication skills, impaired social skills and repetitive/stereotyped behaviors which began at age 15-16 months. Follow-up: He is still primarily non-verbal. His language did not return. His academic level is still far below his age. He still has sensory issues. His eye contact has improved with hours and hours of ABA-type therapy, speech therapy, social therapy, and occupational therapy, but he still holds on obvious Autism diagnosis that was not evident until the vaccinations listed above were given to him. My daughter did not receive these vaccines and she is neurotypical. We have him in speech therapy, occupational therapy & developmental therapy, but he has speech & language and is learning to talk again. Since the vaccination he has not progressed developmentally. He seems to function at about a 16-18 month-old and will be 4 y.o. on mon.
Itching, redness (size of a hand). Pain around neck and should. Low grade fever.
This case was reported by a physician via call center representative and described the occurrence of injection site pain in a elderly female patient who received SHINGRIX for prophylaxis. Co-suspect products included Flu Seasonal QIV Dresden (Influenza vaccine Quadrivalent unspecified season) for prophylaxis. The patient's past medical history included hiatal hernia and esophageal acid reflux. Concurrent medical conditions included rheumatoid factor positive. On an unknown date, the patient received the 1st dose of SHINGRIX and Influenza vaccine Quadrivalent unspecified season. On an unknown date, less than a day after receiving SHINGRIX and Influenza vaccine Quadrivalent unspecified season and less than a day after receiving SHINGRIX and Influenza vaccine Quadrivalent unspecified season, the patient experienced injection site pain and influenza-like symptoms. On an unknown date, the outcome of the injection site pain and influenza-like symptoms were recovered/resolved. It was unknown if the reporter considered the injection site pain and influenza-like symptoms to be related to SHINGRIX and Influenza vaccine Quadrivalent unspecified season. Additional details were reported as follows: The age at vaccination was not reported. The reporter was a dentist and patient. The reporter stated that she received the 1st dose of SHINGRIX a few months before the date of reporting and received a flu shot (unknown manufacturer) on the same day. The patient stated that she received the flu vaccine in one arm and the SHINGRIX vaccine in the other arm. The patient stated that she experienced pain at both injection sites and could not lay down on either arm. The patient stated that she also experienced flu like symptoms after receiving both vaccines that day. The symptoms resolved in a few days. It was unknown if the reporter considered the injection site pain and influenza-like symptoms to be related to SHINGRIX and Influenza vaccine Quadrivalent unspecified season. For tolerance after 2nd dose refer case US2019036192.
"Period" lasts for 10 days (6 days no bleeding)/Bleeding for 49 days (12 days no bleeding)/bleeding for 3 days (3 days no bleeding)/Bleeding for 5 days (8 days no bleeding); Rash develops all over arms, legs, and stomach.; This is a spontaneous report from a contactable consumer (patient). A 33-year-old, non-pregnant female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Batch/Lot Number: Er8730, Expiration date: Unknown), via an unspecified route of administration, administered in left arm on 23Mar2021 14:00 (at the age of 33-year-old) as dose 1, single for COVID-19 immunization in pharmacy or drug store. No other vaccine was administered in four weeks. The patient did not have any known allergies. The patient did not have Covid prior vaccination. The patient was not tested for Covid post vaccination. Medical history was none, and concomitant medications were not reported. On 29Mar2021, the patient experienced rash develops all over arms, legs, and stomach. The patient had not eaten anything different or been outside to catch a rash from anything. On 06Apr2021, the patient experienced period lasts for 10 days (6 days no bleeding)/bleeding for 49 days (12 days no bleeding)/bleeding for 3 days (3 days no bleeding)/bleeding for 5 days (8 days no bleeding). On 06Apr2021: Patient went to dermatologist for the rash, given an oral cream and a steroid shot. Dermatologist told this could be from the COVID vaccine and she should still get a second dose, this was not considered severe. Rash starts to clear up a few days after this. It was reported that, from 06Apr2021- 15Apr2021: Period lasts for 10 days (6 days no bleeding), 22Apr2021 - 09Jun2021: bleeding for 49 days (12 days no bleeding), 22Jun2021-24Jun2021 bleeding for 3 days (3 days no bleeding), 28Jun2021 - 02Jul2021: bleeding for 5 days (heavy thought this was a real period) (9 days no bleeding), 12Jul2021- 16Jul2021: bleeding for 5 days (8 days no bleeding), 25Jul2021- 29Jul2021: bleeding for 5 days (8 days no bleeding), 07Aug2021- 12Aug2021: bleeding for 5 days. The events resulted in doctor or other healthcare professional office/clinic visit. The patient underwent lab tests and procedures which included ultrasound: unknown results on an unspecified date. Therapeutic measures were taken as a result of the events with ultrasound, oral cream and a steroid shot. The outcome of the events was recovered with sequelae on an unspecified date in 2021.  Follow-up attempts are completed. No further information is expected.
SORE ARM; This spontaneous report received from a patient via a company representative concerned a patient of unspecified age and sex. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: unknown) dose was not reported, administered on MAR-2021 for prophylactic vaccination. The company was unable to perform follow up to request batch number.  No concomitant medications were reported. On MAR-2021, the subject experienced sore arm. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of sore arm was not reported. This report was non-serious.